Journal article
Far infrared ray (FIR) therapy: An effective and oncological safe treatment modality for breast cancer related lymphedema.
- Li K Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
- Xia L Department of Oral Pathology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.
- Liu NF Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China.
- Nicoli F Department of Plastic and Reconstructive Surgery, University of Rome "Tor Vergata", Italy; Plastic Reconstructive and Aesthetic Surgery Unit, Villa Salaria Clinic, Rome; Department of Plastic and Reconstructive Surgery, St Thomas' & St Mark's Hospitals, London, UK.
- Constantinides J Department of Plastic and Reconstructive Surgery, St Thomas' & St Mark's Hospitals, London, UK.
- D'Ambrosia C School of Medicine, Columbia University, New York, USA.
- Lazzeri D Plastic Reconstructive and Aesthetic Surgery Unit, Villa Salaria Clinic, Rome.
- Tremp M Department of Plastic, Reconstructive, Aesthetic and Hand Surgery, University Hospital Basel, Spitalstrasse 21, 4031 Basel, Switzerland.
- Zhang JF Plastic Surgery Department, Hangzhou First People's Hospital, Hangzhou, Zhejiang, China. Electronic address: Zhjuf@vip.sina.com.
- Zhang YX Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China. Electronic address: zhangyixin6688@hotmail.com.
- 2017-05-24
Published in:
- Journal of photochemistry and photobiology. B, Biology. - 2017
Breast cancer
Breast cancer-related lymphedema
Clinical research
Far infrared ray
Lymphedema
Adult
Aged
Aged, 80 and over
Biomarkers, Tumor
Breast
Breast Cancer Lymphedema
CA-125 Antigen
Cell Cycle Checkpoints
Cell Line
Cell Proliferation
Cell Survival
Female
Humans
Infrared Rays
MCF-7 Cells
Mastectomy
Middle Aged
Phototherapy
Ultrasonography
English
BACKGROUND
The incidence of breast cancer related lymphedema is approximately 5%. Far infrared ray (FIR) treatment can potentially reduce fluid volume and extremity circumference as well as the frequency of dermato-lymphangitis (DLA). However, there is no published data on the oncological safety of FIR and the potential for activation of any residual breast cancer cells. The aim of this study is to investigate the safety of far infrared ray (FIR) treatment of postmastectomy lymphedema, clinically and in vitro.
METHODS
Patients who underwent mastectomy more than 5years ago complicated by upper extremity lymphedema for more than 1year were included. The enrolled patients were divided into an FIR treatment group and a control group (conservative treatment using bandage compression). Outcome measures included tumor markers (CA153, CA125), ultrasonography of relevant structures and monitoring for adverse reactions 1year after treatment. For the in vitro part of the study, the effects of FIR on human breast adenocarcinoma cell lines (MCF7, MDA-MB231) compared to the effects of FIR on human dermal fibroblasts as a control were considered. The viability, proliferation, cell cycle and apoptotic statistics of the adenocarcinoma and human dermal fibroblast cell lines were analyzed and compared.
RESULTS
Results demonstrated that after treatment with FIR, tumor marker (CA153, CA125) concentrations in both the FIR and control groups were not elevated. There was no statistically significant difference between FIR and control group marker expression (p>0.05). Furthermore, no patients were diagnosed with lymphadenectasis or newly enlarged lymph nodes in these two groups. Importantly, there were no adverse events in either group. The in vitro experiment indicated that FIR radiation does not affect viability, proliferation, cell cycle and apoptosis of fibroblasts, MCF-7 and MDA-MB-231 cells.
CONCLUSIONS
FIR should be considered as feasible and safe for the treatment of breast cancer related lymphedema patients 5years after mastectomy. FIR does not promote recurrence or metastasis of breast cancer and is a well-tolerated therapy with no adverse reactions.
The incidence of breast cancer related lymphedema is approximately 5%. Far infrared ray (FIR) treatment can potentially reduce fluid volume and extremity circumference as well as the frequency of dermato-lymphangitis (DLA). However, there is no published data on the oncological safety of FIR and the potential for activation of any residual breast cancer cells. The aim of this study is to investigate the safety of far infrared ray (FIR) treatment of postmastectomy lymphedema, clinically and in vitro.
METHODS
Patients who underwent mastectomy more than 5years ago complicated by upper extremity lymphedema for more than 1year were included. The enrolled patients were divided into an FIR treatment group and a control group (conservative treatment using bandage compression). Outcome measures included tumor markers (CA153, CA125), ultrasonography of relevant structures and monitoring for adverse reactions 1year after treatment. For the in vitro part of the study, the effects of FIR on human breast adenocarcinoma cell lines (MCF7, MDA-MB231) compared to the effects of FIR on human dermal fibroblasts as a control were considered. The viability, proliferation, cell cycle and apoptotic statistics of the adenocarcinoma and human dermal fibroblast cell lines were analyzed and compared.
RESULTS
Results demonstrated that after treatment with FIR, tumor marker (CA153, CA125) concentrations in both the FIR and control groups were not elevated. There was no statistically significant difference between FIR and control group marker expression (p>0.05). Furthermore, no patients were diagnosed with lymphadenectasis or newly enlarged lymph nodes in these two groups. Importantly, there were no adverse events in either group. The in vitro experiment indicated that FIR radiation does not affect viability, proliferation, cell cycle and apoptosis of fibroblasts, MCF-7 and MDA-MB-231 cells.
CONCLUSIONS
FIR should be considered as feasible and safe for the treatment of breast cancer related lymphedema patients 5years after mastectomy. FIR does not promote recurrence or metastasis of breast cancer and is a well-tolerated therapy with no adverse reactions.
- Language
-
- English
- Open access status
- closed
- Identifiers
-
- DOI 10.1016/j.jphotobiol.2017.05.011
- PMID 28535427
- Persistent URL
- https://sonar.ch/global/documents/299334
Statistics
Document views: 35
File downloads: